肠道微生物群对胶质母细胞瘤免疫环境的调节作用

Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota.

作者信息

Green George B H, Cox-Holmes Alexis N, Potier Anna Claire E, Marlow Gillian H, McFarland Braden C

机构信息

Department of Cell, Developmental and Integrative Biology, Birmingham, AL 35294, USA.

Undergraduate Cancer Biology Program, Birmingham, AL 35294, USA.

出版信息

Biomedicines. 2024 Oct 23;12(11):2429. doi: 10.3390/biomedicines12112429.

DOI:10.3390/biomedicines12112429

PMID:39594997

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11591702/

Abstract

Studies increasingly support the role of the gut microbiota in glioma development and treatment, although the exact mechanisms remain unclear. Research indicates that the gut microbiota can influence glioma progression, response to therapies, and the effectiveness of treatments like immunotherapy, with certain microbial compositions being linked to better outcomes. Additionally, the gut microbiota impacts the tumor microenvironment, affecting both tumor growth and the response to treatment. This review will explore glioma, the gut microbiota, and how their interaction shapes glioma development and therapy responses. Additionally, this review examines the influence of gut microbiota metabolites, such as short-chain fatty acids (SCFAs) and tryptophan, on glioma development and treatment. It also explores gut microbiome signaling via pattern recognition receptors, and the role of molecular mimicry between microbial and tumor antigens in glioblastoma, and if these interactions affect glioma development and treatment.

摘要

越来越多的研究支持肠道微生物群在胶质瘤发生发展和治疗中的作用，尽管确切机制仍不清楚。研究表明，肠道微生物群可影响胶质瘤的进展、对治疗的反应以及免疫疗法等治疗方法的有效性，某些微生物组成与更好的治疗结果相关。此外，肠道微生物群会影响肿瘤微环境，既影响肿瘤生长，也影响对治疗的反应。本综述将探讨胶质瘤、肠道微生物群，以及它们之间的相互作用如何塑造胶质瘤的发生发展和治疗反应。此外，本综述还研究了肠道微生物群代谢产物，如短链脂肪酸（SCFAs）和色氨酸，对胶质瘤发生发展和治疗的影响。它还探讨了通过模式识别受体的肠道微生物群信号传导，以及微生物与肿瘤抗原之间的分子模拟在胶质母细胞瘤中的作用，以及这些相互作用是否影响胶质瘤的发生发展和治疗。